Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Product Pipeline Updates
RESEARCH TRIANGLE PARK, N.C.—Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for…